NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the hearing to determine whether to approve a proposed class action settlement that would benefit purchasers of Akers Biosciences, Inc. (“Akers”) common stock  (NASDAQ:AKER), originally s...

Akers Biosciences (NASDAQ: AKER ): Q2 GAAP EPS of -$0.06. More news on: Akers Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, report...